AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12771037
Drug: Oleic acid
RxNorm normalized name: Oleic Acid
DrugBank: Oleic Acid (DB04224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oleic acid (OA), 4 g daily for 3 months
Trial: 8463443
Drug: Imipramine (maximum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (maximum dose of 300 mg per day)
Trial: 4087830
Drug: Oral rifampicin
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral rifampicin (600 mg)
Trial: 4087830
Drug: Intravenous rifampicin
RxNorm normalized name: rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous rifampicin (600 mg)
Trial: 23320436
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg gemigliptin qd
Trial: 23320436
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg sitagliptin qd
Trial: 23320436
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg gemigliptin bid
Trial: 23320436
Drug: gemigliptin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gemigliptin treatment
Trial: 19145494
Drug: Fesoterodine 8
RxNorm normalized name: fesoterodine 8 mg oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fesoterodine 8 mg after high-fat breakfast
Trial: 15259543
Drug: Active desensitizing
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active desensitizing agent (UltraEZ) applied daily for 14 days prior to whitening for 30 minutes.
Trial: 15259543
Drug: Placebo (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (same formulation as UltraEZ without desensitizing agents) applied daily for 14 days prior to whitening for 30 minutes.
Trial: 11078068
Drug: Prophylactic perioperative
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic perioperative prednisolone treatment
Trial: 29030775
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no prednisolone treatment)
Trial: 1555812
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of hydroxyzine (10 mg)
Trial: 1555812
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of buspirone (5 mg)
Trial: 1555812
Drug: Multi-dose of
RxNorm normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-dose of buspirone (5 mg)
Trial: 1555812
Drug: Multi-dose of
RxNorm normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-dose of chlordiazepoxide (5 mg)
Trial: 1555812
Drug: Multi-dose of
RxNorm normalized name: VIAL ADAPTER MULTI-DOSE ALARIS #2205E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-dose of hydroxyzine (10 mg)
Trial: 3894589
Drug: Cisplatin 50
RxNorm normalized name: cisplatin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 50 mg/m2 every 21 days (regimen 1)
Trial: 3894589
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 every 21 days (regimen 2)
Trial: 23558369
Drug: Fascia iliaca
RxNorm normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascia iliaca block (30 mL 0.5% ropivacaine)
Trial: 19920766
Drug: Matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo (daily for 2 weeks)
Trial: 18971523
Drug: Azelnidipine 8
RxNorm normalized name: Azelnidipine
DrugBank: Azelnidipine (DB09230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelnidipine 8 mg monotherapy
Trial: 18971523
Drug: Temocapril 2
RxNorm normalized name: temocapril
DrugBank: Temocapril (DB08836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temocapril 2 mg monotherapy
Trial: 18971523
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (azelnidipine and temocapril)
Trial: 12855059
Drug: Successful treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Successful treatments (psychotherapy)
Trial: 12855059
Drug: Naturalistic study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naturalistic study of successful treatments
Trial: 8791947
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate 400 mg b.d. plus clarithromycin 500 mg t.d.s. for the first 2 weeks
Trial: 8791947
Drug: Ranitidine bismuth
RxNorm normalized name: RANITIDINE BISMUTH CITRATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine bismuth citrate 400 mg b.d. for 4 weeks
Trial: 1281625
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine and hydromorphone
Trial: 31424649
Drug: simple intravenous
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simple intravenous chemotherapy with cisplatin paclitaxel (TP group)
Trial: 31424649
Drug: gene therapy
RxNorm normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gene therapy + intravenous chemotherapy with cisplatin+paclitaxel (rAd‐p53 + TP group)
Trial: 26502235
Drug: LEDTB group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEDTB group (photodynamic antimicrobial chemotherapy with light‐emitting diode and toluidine blue solution and RMGIC)
Trial: 23839029
Drug: Oral oxycodone
RxNorm normalized name: oxycodone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxycodone (high dose 45 mg/70 kg)
Trial: 23839029
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine (high dose 135 mg/70 kg)
Trial: 23839029
Drug: Oral morphine
RxNorm normalized name: morphine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral morphine (low dose 45 mg/70 kg)
Trial: 16253169
Drug: Late course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late course conformal radiotherapy combined with chemotherapy
Trial: 8322572
Drug: Propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.5 mg.kg‐1
Trial: 10215713
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg.kg‐1 with Propofol
Trial: 10215713
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg.kg‐1 with Thiopentone
Trial: 30666827
Drug: Enalapril 5
RxNorm normalized name: enalapril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 5 mg
Trial: 389843
Drug: Fluocinonide 0.05%
RxNorm normalized name: FLUOCINONIDE 0.05% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluocinonide 0.05% emollient cream
Trial: 29770722
Drug: Betamethasone valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betamethasone valerate 0.1% cream
Trial: 11260007
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide 0.1% cream
Trial: 30302901
Drug: Intralesional triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intralesional triamcinolone acetonide (TRA) injection
Trial: 25701560
Drug: 2+1 group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2+1 group (two-dose prime and boost)
Trial: 23599118
Drug: Topical anakinra,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anakinra, 2.5% (n = 30)
Trial: 23599118
Drug: Topical anakinra,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical anakinra, 5% (n = 15)
Trial: 20693429
Drug: High-dose daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose daunorubicin
Trial: 20693429
Drug: Standard-dose idarubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose idarubicin
Trial: 26330288
Drug: Adjunctive placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive placebo
Trial: 30509296
Drug: Heparin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin treatment
Trial: 15514727
Drug: Refracterin, 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Refracterin, 300 mg/day for 3 days
Trial: 18794027
Drug: Aspirin 160
RxNorm normalized name: aspirin 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 160 mg
Trial: 11524065
Drug: Aspirin 80
RxNorm normalized name: aspirin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 80 mg + Warfarin 1 mg
Trial: 3546420
Drug: 2% topical
RxNorm normalized name: A/T/S 2% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% topical ketoconazole cream (once or twice daily)
Trial: 27738812
Drug: Green/roasted coffee
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green/roasted coffee blend (35/65), 3 servings/day providing 510.6 mg hydroxycinnamic acids and 121.2 mg caffeine/day for 8 weeks
Trial: 27257953
Drug: Oxandrolone 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone 0.1 mg/kg/day in MCT oil
Trial: 27257953
Drug: Oxandrolone 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone 0.2 mg/kg/day aqueous solution
Trial: 27257953
Drug: Oxandrolone 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxandrolone 0.1 mg/kg/day aqueous solution
Trial: 15850466
Drug: Lamivudine-interferon (9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamivudine-interferon (9 MU, t.i.w.) in combination
Trial: 27655061
Drug: Diagnostic testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnostic testing before antibiotic prescribing
Trial: 30865149
Drug: 3 dosing
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 dosing protocols of motor learning-based therapy, identical number of 2-hour sessions over different total calendar weeks
Trial: 26673246
Drug: p-synephrine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: p-synephrine (3 mg·kg(‐1))
Trial: 2180259
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose bromocriptine
Trial: 9196546
Drug: Pyridostigmine bromide
RxNorm normalized name: Pyridostigmine Bromide
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridostigmine bromide (30 mg)
Trial: 14739855
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control group, n=9)
Trial: 18041489
Drug: Zolpidem (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem (10 mg)
Trial: 2201730
Drug: Triazolam (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam (0.25 mg)
Trial: 12680738
Drug: Temazepam (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temazepam (30 mg)
Trial: 25873729
Drug: Low-dose unfractionated
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose unfractionated heparin (50 U/kg)
Trial: 25873729
Drug: Standard-dose unfractionated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose unfractionated heparin (85 U/kg or 60 U/kg with glycoprotein IIb/IIIa inhibitors, with ACT guidance)
Trial: 25873729
Drug: ACT≤300 s
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACT≤300 s (in patients not receiving planned glycoprotein IIb/IIIa inhibitors)
Trial: 23703418
Drug: Blind local
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blind local steroid injection
Trial: 19482767
Drug: Nebulized 2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized 2% lidocaine at 4 mg/kg
Trial: 15365964
Drug: 3 mg/kg/dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg/dialysis iron-sucrose for Group A (iron deficient)
Trial: 15365964
Drug: 0.3 mg/kg/dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg/dialysis iron-sucrose for Group B (iron-replete)
Trial: 15365964
Drug: 1 mg/kg/dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg/dialysis iron-sucrose for Group A (after initial treatment)
Trial: 11352248
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg subcutaneously twice weekly) added to standard therapies for WG
Trial: 15496641
Drug: Etanercept (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etanercept (25 mg subcutaneously twice weekly)
Trial: 25596138
Drug: BUD/FM BAI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUD/FM BAI 2 × 160/4.5 μg bid
Trial: 21726291
Drug: Antacid tablet
RxNorm normalized name: Calcium Carbonate 500 MG Oral Tablet, Chewable [GOOD SENSE ANTACID TABLETS]
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antacid tablet
Trial: 21726291
Drug: Gum arabic
RxNorm normalized name: Gum arabic
DrugBank: Acacia (DB10451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum arabic lozenge
Trial: 30472992
Drug: Intensive periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive periodontal treatment (IPT)
Trial: 16772796
Drug: Bisphosphonate-type compounds
RxNorm normalized name: collagen type I
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonate-type compounds (calcitonin, clodronate, alendronate)
Trial: 26372
Drug: Intravenous phentolamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous phentolamine
Trial: 7525652
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (HDMTX and LDMTX)
Trial: 26333801
Drug: Mindfulness-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based therapy (MT)
Trial: 15730346
Drug: Paroxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (20 mg daily)
Trial: 10682150
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg zanamivir powder for inhalation
Trial: 10682150
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg zanamivir powder for inhalation plus 6.4 mg zanamivir nasal spray
Trial: 8922541
Drug: Fasting insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fasting insulin levels of 8.1-12.9 mU/1
Trial: 8922541
Drug: Fasting insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fasting insulin levels of 13.0 mU/1 or more
Trial: 29332135
Drug: Simultaneous GnRHa
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous GnRHa treatment
Trial: 27521254
Drug: Protein intake
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein intake ≥60 g/d
Trial: 21134505
Drug: Letrozole 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 7.5 mg daily for 2 days followed by 800 mcg vaginal misoprostol
Trial: 21134505
Drug: Letrozole 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 7.5 mg combined with 200 mg mifepristone
Trial: 11253444
Drug: NRT use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NRT use among patients offered prescription by a physician
Trial: 27987236
Drug: Naltrexone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (100 mg orally)
Trial: 3490559
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation during thyroxine therapy
Trial: 9599737
Drug: Before treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Before treatment
Trial: 29729429
Drug: Clindamycin administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin administered intravenously 30 minutes before incision and every 8 hours for 24 hours post-operation
Trial: 29729429
Drug: Sterile saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline administered
Trial: 23644179
Drug: Rosuvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin (40 mg)
Trial: 20202516
Drug: Celecoxib (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (200 mg orally twice daily for 5 days) followed by Rosuvastatin (40 mg)
Trial: 11212905
Drug: DTIC 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC 750 mg/m2 IV day 1 every 28 days (Arm A)
Trial: 11212905
Drug: DTIC 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTIC 200 mg/m2 IV days 1-5 every 28 days (Arm B)
Trial: 2986275
Drug: Alginate/antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alginate/antacid
Trial: 25547064
Drug: High-dose vancomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vancomycin
Trial: 25547064
Drug: Conventional-dose vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional-dose vancomycin
Trial: 12631411
Drug: Artemisinin 250
RxNorm normalized name: ARTEMISININ
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin 250 (250 mg artemisinin)
Trial: 12631411
Drug: beta‐cyclodextrin‐artemisinin complex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beta‐cyclodextrin‐artemisinin complex (150 mg artemisinin)
Trial: 1589726
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment with antibiotics (Control)
Trial: 3840029
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g sucralfate
Trial: 20594781
Drug: Aged garlic
RxNorm normalized name: Garlic 600 MG Oral Tablet [KYOLIC AGED GARLIC EXTRACT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aged garlic extract (960 mg containing 2.4 mg S-allylcysteine) daily for 12 weeks
Trial: 9708721
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and clavulanate every 12 hours (875 mg amoxicillin; 125 mg clavulanate)
Trial: 9708721
Drug: Amoxicillin and
RxNorm normalized name: omeprazole, amoxicillin and rifabutin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin and clavulanate every 8 hours (500 mg amoxicillin; 125 mg clavulanate)
Trial: 9566550
Drug: VaxSyn (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VaxSyn (recombinant HIV envelope subunit vaccine)
Trial: 1897329
Drug: 200 IU
RxNorm normalized name: Vitamin E 200 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 IU of salmon calcitonin daily as a nasal spray
Trial: 23697602
Drug: Lapatinib (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapatinib (1000 mg/day) plus paclitaxel (70 mg/m2 per week, 3 of every 4 weeks) plus trastuzumab
Trial: 17353512
Drug: Phenylephrine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine infusion to elevate nocturnal blood pressure to mean daytime values
Trial: 8269785
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy combined with daily oral aspirin 100mg
Trial: 3666663
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg diltiazem tablet (one tablet bid for 7 days)
Trial: 3666663
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg diltiazem tablet (two tablets bid for 7 days)
Trial: 29101186
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (target <120 mm Hg) with mean arterial pressure reduction <20 mm Hg
Trial: 29101186
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (target <120 mm Hg) with mean arterial pressure reduction between 20 and <40 mm Hg
Trial: 29101186
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (target <140 mm Hg)
Trial: 24720376
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1200 mg bid for 8 weeks
Trial: 22848894
Drug: Immediately loaded
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediately loaded implant-supported prosthesis (test group)
Trial: 15977096
Drug: Ropivacaine 0.2
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2 % plus 1 mg/kg tramadol HCl (Group RT)
Trial: 15977096
Drug: Ropivacaine 0.2
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2 % plus 0.1 mg/kg morphine HCl (Group RM)
Trial: 31093952
Drug: TNHH 0.2–1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNHH 0.2–1.8 mg/kg